Milestone Pharmaceuticals (MIST) Competitors $0.89 +0.07 (+8.80%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.89 0.00 (-0.21%) As of 04/17/2025 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIST vs. DERM, ACRS, IPHA, MOLN, PBYI, KRRO, CTNM, RAPT, TNGX, and TARAShould you be buying Milestone Pharmaceuticals stock or one of its competitors? The main competitors of Milestone Pharmaceuticals include Journey Medical (DERM), Aclaris Therapeutics (ACRS), Innate Pharma (IPHA), Molecular Partners (MOLN), Puma Biotechnology (PBYI), Korro Bio (KRRO), Contineum Therapeutics (CTNM), RAPT Therapeutics (RAPT), Tango Therapeutics (TNGX), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Milestone Pharmaceuticals vs. Journey Medical Aclaris Therapeutics Innate Pharma Molecular Partners Puma Biotechnology Korro Bio Contineum Therapeutics RAPT Therapeutics Tango Therapeutics Protara Therapeutics Journey Medical (NASDAQ:DERM) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership. Does the MarketBeat Community prefer DERM or MIST? Milestone Pharmaceuticals received 79 more outperform votes than Journey Medical when rated by MarketBeat users. However, 85.71% of users gave Journey Medical an outperform vote while only 68.55% of users gave Milestone Pharmaceuticals an outperform vote. CompanyUnderperformOutperformJourney MedicalOutperform Votes685.71% Underperform Votes114.29%Milestone PharmaceuticalsOutperform Votes8568.55% Underperform Votes3931.45% Do insiders & institutionals have more ownership in DERM or MIST? 7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 13.2% of Journey Medical shares are owned by company insiders. Comparatively, 9.9% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is DERM or MIST more profitable? Milestone Pharmaceuticals has a net margin of 0.00% compared to Journey Medical's net margin of -31.74%. Journey Medical's return on equity of -132.10% beat Milestone Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Journey Medical-31.74% -132.10% -26.90% Milestone Pharmaceuticals N/A -151.82%-49.85% Which has stronger valuation & earnings, DERM or MIST? Journey Medical has higher revenue and earnings than Milestone Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJourney Medical$56.13M2.57-$3.85M-$0.74-8.45Milestone Pharmaceuticals$1M47.43-$59.69M-$0.68-1.31 Do analysts rate DERM or MIST? Journey Medical currently has a consensus price target of $9.88, indicating a potential upside of 58.00%. Milestone Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 1,812.48%. Given Milestone Pharmaceuticals' higher possible upside, analysts clearly believe Milestone Pharmaceuticals is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Journey Medical 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Milestone Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has more risk and volatility, DERM or MIST? Journey Medical has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Does the media favor DERM or MIST? In the previous week, Journey Medical and Journey Medical both had 1 articles in the media. Journey Medical's average media sentiment score of -1.00 equaled Milestone Pharmaceuticals'average media sentiment score. Company Overall Sentiment Journey Medical Negative Milestone Pharmaceuticals Negative SummaryJourney Medical beats Milestone Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIST vs. The Competition Export to ExcelMetricMilestone PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$47.43M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-1.106.8921.8417.80Price / Sales47.43230.57380.2597.71Price / CashN/A65.6738.2634.64Price / Book1.785.936.443.98Net Income-$59.69M$142.99M$3.22B$247.73M7 Day Performance15.25%4.43%2.85%1.80%1 Month Performance-62.65%-12.72%-8.66%-6.97%1 Year Performance-45.47%-9.42%11.46%1.29% Milestone Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MISTMilestone Pharmaceuticals1.4836 of 5 stars$0.89+8.8%$17.00+1,812.5%-49.2%$47.43M$1M-1.1030Short Interest ↑Negative NewsGap UpHigh Trading VolumeDERMJourney Medical2.2147 of 5 stars$6.96-3.2%$9.88+41.9%+61.9%$145.39M$56.13M-7.4090Short Interest ↑Positive NewsGap UpHigh Trading VolumeACRSAclaris Therapeutics1.8451 of 5 stars$1.33-5.0%$11.67+777.2%-7.3%$143.53M$18.72M-2.56100Positive NewsGap UpIPHAInnate Pharma1.9875 of 5 stars$1.71-6.6%$11.50+572.5%-17.9%$143.35M$12.63M0.00220Gap DownMOLNMolecular Partners1.6254 of 5 stars$3.54-0.8%$12.00+239.0%+1.5%$142.93M$4.97M-1.65180PBYIPuma Biotechnology3.3417 of 5 stars$2.83-2.4%$7.00+147.3%-44.7%$140.40M$230.47M5.90200Analyst UpgradeKRROKorro Bio1.388 of 5 stars$14.93+3.8%$136.33+813.2%-79.9%$140.18M$2.27M-1.5970Analyst ForecastNews CoveragePositive NewsGap UpCTNMContineum Therapeutics2.1582 of 5 stars$5.37-7.4%$24.80+361.8%-70.0%$138.93M$50M-1.1031Positive NewsGap DownRAPTRAPT Therapeutics3.6135 of 5 stars$1.05-0.9%$4.00+281.0%-90.2%$138.61M$1.53M-0.3880Short Interest ↑News CoverageTNGXTango Therapeutics2.0971 of 5 stars$1.27flat$12.33+871.1%-82.7%$137.30M$42.07M-1.0890Analyst RevisionNews CoverageGap UpTARAProtara Therapeutics1.8158 of 5 stars$3.70-5.1%$22.50+508.1%+42.9%$136.04MN/A-1.3130Analyst ForecastNews CoveragePositive NewsGap Up Related Companies and Tools Related Companies DERM Alternatives ACRS Alternatives IPHA Alternatives MOLN Alternatives PBYI Alternatives KRRO Alternatives CTNM Alternatives RAPT Alternatives TNGX Alternatives TARA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIST) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
